参考文献/References:
[1] BUSKWOFIE A, DAVID-WEST G, CLARE C A. A review of cervical cancer: incidence and disparities[J]. Journal of the National Medical Association, 2020,112(2): 229-232.
[2] 高红敏, 杨红英, 刘鑫. 血清中microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J]. 现代检验医学杂志, 2020, 35(6): 85-86, 182. GAO Hongmin, YANG Hongying, LIU Xin. Value analysis of serum microRNA-106b in early diagnosis of cervical cancer[J]. Journal of Modern Laboratory Medicine, 2020, 35(6): 85-86, 182.
[3] WANG Ziwei, LIU Yan, ZHANG Jun, et al. An immune-related long noncoding RNA signature as a prognostic biomarker for human endometrial cancer[J]. Journal of Oncology, 2021, 2021: 9972454.
[4] BERSELLI A, BENFENATI F, MARAGLIANO L, et al. Multiscale modelling of claudin-based assemblies: a magnifying glass for novel structures of biological interfaces[J]. Computational and Structural Biotechnology Journal, 2022, 20: 5984-6010.
[5] HAO Shiyu, YANG Chunyan, SONG Peng, et al. CLDN4 promotes growth of acute myeloid leukemia cells via regulating AKT and ERK1/2 signaling[J]. Biochemical and Biophysical Research Communications, 2022, 619: 137-143.
[6] HU Pan, LEI Li, WANG Ying, et al. CLDN4 as a novel diagnostic and prognostic biomarker and its association with immune infiltrates in ovarian cancer[J]. Mediators of Inflammation, 2023, 2023: 1075265.
[7] XU Yichi, PAN Shuya, CHEN Hong, et al. MEX3A suppresses proliferation and EMT via inhibiting Akt signaling pathway in cervical cancer[J]. American Journal of Cancer Research, 2021, 11(4): 1446-1462.
[8] LI Jina, LIU Gaoming, LUO Jiayou, et al. Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study[J]. Scientific Reports, 2022, 12(1): 13994.
[9] FANG Chenyan, ZHANG Ping, YU Aijun, et al. Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without[J]. Gynecologic Oncology, 2021, 162(1): 50-55.
[10] LIAO Yuandong, HUANG Jiaming, LIU Pan, et al. Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer[J]. Oncogene, 2022, 41(13): 1931-1943.
[11] LUO Aoran, LAN Xiaoxiao, QIU Qiongzi, et al. LncRNA SFTA1P promotes cervical cancer progression by interaction with PTBP1 to facilitate TPM4 mRNA degradation[J]. Cell Death & Disease, 2022, 13(11): 936.
[12] HAN Sai, LIU Xiaoli, JU Shuang, et al. New mechanisms and biomarkers of lymph node metastasis in cervical cancer: reflections from plasma proteomics[J]. Clinical Proteomics, 2023, 20(1): 35.
[13] BERSELLI A, ALBERINI G, BENFENATI F, et al. Computational study of ion permeation through claudin-4 paracellular channels[J]. Annals of the New York Academy of Sciences, 2022, 1516(1): 162-174.
[14] JIE Youkun, YE Lu, CHEN He, et al. ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer[J]. Bioengineered, 2020, 11(1): 872-882.
[15] WANG Hao, XU Hongfa, MA Feng, et al. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression[J]. Cell Death & Disease, 2020, 11(4): 225.
[16] LIN Heng, KRYCZEK I, LI Shasha, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance[J]. Cancer Cell, 2021, 39(4): 480-493. e6.
[17] KROEMER G, ZITVOGEL L. Subversion of calreticulin exposure as a strategy of immune escape[J]. Cancer Cell, 2021, 39(4): 449-451.
[18] ZHU Jiaqi, JIANG Qi. Twist1-mediated transcriptional activation of Claudin-4 promotes cervical cancer cell migration and invasion[J]. Oncology Letters, 2023, 26(2): 335.
[19] FUJIWARA-TANI R, MORI S, OGATA R, et al. Claudin-4: a new molecular target for epithelial cancer therapy[J]. International Journal of Molecular Sciences, 2023, 24(6): 5494.
[20] LUO Jie, WANG Huaiming, CHEN Huanjie, et al. CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of the PI3K/Akt signalling pathway[J]. Experimental Physiology, 2020, 105(6): 979-988.
相似文献/References:
[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周 静,李 智,周 玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王 纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘 鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(06):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(06):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]方 芳,吴 玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(06):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]